Paion AG reduced its loss in the first nine months of 2011 but said that difficult conditions on the capital markets and restrained investment by the pharmaceutical industry had delayed the planned out-licensing of two products. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals